(PharmaNewsWire.Com, May 14, 2018 ) Asia Pacific Plasma Fractionation Market was worth USD 3.88 billion in 2016 and is projected to be growing at a CAGR of 9.6%, to touch USD 6.14 billion by 2021. Plasma, which constitutes about 55% of blood by volume consists of several different proteins numbering into the thousands, and other substances like minerals, hormones, etc. There are many therapeutic uses for the proteins present in plasma. For example, Albumin is commonly used to rejuvenate and maintain blood volume after traumatic injury, during surgery and during the exchange of plasma.
Plasma Fractionation consists of the fractionation of blood into its constituent parts of red cells, white cells and platelets, which are suspended in plasma. The plasma is studied for deficiencies relating to blood disorders and replaced or supplemented with a cure.
The growth of the Asia Pacific Plasma Fractionation Market is mainly driven by factors such as the growing use of immunoglobulins, which are basically antibodies, the increasing prevalence of immune and bleeding disorders, growing occurrence of Alpha-1 Antitrypsin deficiency and the aging population which is prone to blood related ailments. However, adversarial reactions related with the procedure of plasma fractionation and transfer, high costs of plasma products and unfavourable reimbursement policies are the main constraints of market growth.
The Asia Pacific Plasma Fractionation Market is segmented on the basis of Product, Application, End User and Geography. Based on Product, the market is divided into Albumin, Immunoglobulin, Factor VIII, and Protease Inhibitors. Based on Application, the Plasma Fractionation Market is segmented into Neurology, Haematology, Rheumatology, Pulmonology, and Immunology. Based on the End User, it is categorized into Hospital and Clinical Laboratories.
The Asia Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Factors such as growing elderly population with immunity and blood disorders, and growing disposable incomes due to emerging economies in countries such as India and China are expected to lead the growth of the market in this region. In fact, Asia Pacific is the fast developing Plasma Fractionation market which is reflected in its CAGR, which is the highest globally. Availability of humongous untapped markets and enormous population base are driving the growth in the Aisa-Pacific Plasma Fractionation Market.
The significant players in the Asia Pacific Plasma Fractionation market are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
